Table 1.
Complete response (%) in total population by phase and chemotherapy treatment following oral administration of rolapitant
| MEC or AC trial, %50
|
P-value | HEC1 and HEC2 trials; cisplatin-based, %49
|
P-value | |
|---|---|---|---|---|
| ROL (n=666) vs CON (n=666) | ROL (n=535) vs CON (n=535) | |||
| Acute phase (0–24 h) | 83.5 vs 80.3 | 0.1425 | 83.6 vs 76.6 | 0.0045 |
| Delayed phase (24–120 h) | 71.3 vs 61.6 | 0.0002 | 71.4 vs 60.2 | 0.0001 |
| Overall phase (0–120 h) | 68.6 vs 57.8 | <0.0001 | 68.8 vs 58.5 | 0.0005 |
Abbreviations: AC, anthracycline and cyclophosphamide; CON, control; h, hours; HEC, highly emetogenic chemotherapy; MEC, moderately emetogenic chemotherapy; ROL, rolapitant.